Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scott_jiminez who started this subject	8/19/2003 7:52:13 AM
From: scott_jiminez	of 278

Parkinson's patient given GAD gene therapy. Front page article in today's NYT (http://www.nytimes.com/2003/08/19/science/19GENE.html?hp requires [free] login) reporting 55 year-old Parkinson's patient received AAV-GAD...thus representing not only the inherent risk of unanticipated viral dissemination but a somewhat novel approach of using inhibition of 'brain activity' (GAD catalyzes the production GABA, a major inhibitory neurotransmitter) rather than the direct production of dopamine. The lead surgeon has close ties to a gene therapy company (Neurologix). This, along with convincing suggestions that the science was neither rigorous nor compelling to support this therapy at this time, will likely turn out to be one more black eye for gene therapy. And it will (obviously) reinforce the impression that most biotech companies in general, and their MD and or Ph.D. officers in particular, have an equal or greater concern for expediency and building a lucrative company in their image, than a Hippocratic notion of medicine.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next